DURECT Corporation

🗓 Founded 1998👥 122 employees💰 Last funded Jan 2021
Pharmaceutical Manufacturing🌐 durect.com
Website LinkedIn
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. Larsucosterol (also known as DUR-928), DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and has been exclusively licensed to Innocoll Pharmaceuticals for development and commercialization in the United States. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
1998
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in DURECT Corporation?
DURECT Corporation has 1 investors on record on gritt.io.
When did DURECT Corporation last raise funding?
The most recent investment in DURECT Corporation recorded on gritt.io was in January 2021.
When was DURECT Corporation founded?
DURECT Corporation was founded in 1998.
What industry is DURECT Corporation in?
DURECT Corporation operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.